- Sonnet BioTherapeutics Holdings Inc SONN announced that the safety of SON-1010 dosing has been formally reviewed in both the current Phase 1 clinical trials, and the company is now enrolling the final dose cohort in the cancer trial.
- Of the 15 patients from the first five cohorts of SB101 evaluable for follow-up at this latest cutoff, 9 had stable disease at the first follow-up scan, 4 of which were already progressing at study entry.
- At four months of follow-up, 5 of 14 patients remained stable at the second scan, suggesting the clinical benefit of SON-1010 in 36% of patients.
- The first patient dosed with an aggressive endometrial sarcoma had target tumor shrinkage with complete resolution of ascites at one point and has been clinically stable for nearly a year.
- SON-1010 has been safe and tolerable at all doses tested to date, with adverse events generally mild/moderate in intensity and transient.
- Chardan Capital maintains a Buy rating on the stock with a price target of $17, down from $22.
- Price Action: SONN shares are down 8.97% at $0.30 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: BiotechNewsPenny StocksHealth CarePrice TargetAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in